Dave Feldman

Author's posts

BREAKING: Our Paper on Low Carb, LDL Cholesterol, and the LMHR Phenotype is Now Available

IMPORTANT UPDATE 1-28-2022: Our paper is now finalized with this guest post from Nick Norwitz now fully updated. Thanks again to the many wonderful readers who contributed their efforts in our final edit. The final version of the Lean Mass Hyper-Responder (LMHR) paper was just released! I’m pleased to report that, even in the early …

Continue reading

Announcement: $20,000 Donation for Lipid Triad Analysis

BREAKING: Last night I posted a tweet (see below) curious if any data scientists would be interested in querying one of the major longitudinal datasets (such as UK Biobank) on the “Lipid Triad” (high LDL-C + high HDL-C + low triglycerides) vs All Cause Mortality. To my great surprise, an anonymous donor has come forward …

Continue reading

Discussing the LMHR Study on the Diet Doctor Podcast

I had a great chat with Dr. Bret Scher, Medical Director of Diet Doctor, on the newly launched Lean Mass Hyper-responder study. 0:00 Introduction 3:06 Welcome, Dave Feldman 4:06 A rise in cholesterol for people on keto 12:05 Dave’s pushback in his research 20:14 Thoughts on the recent Women’s Health Study paper 29:39 Exciting news …

Continue reading

THE LEAN MASS HYPER-RESPONDER STUDY LAUNCHES TODAY

The Citizen Science Foundation is proud to announce the launch of the Lean Mass Hyper-responder study, effective immediately. This research will be conducted in partnership with the Lundquist Institute for Biomedical Innovation at Harbor-UCLA. For official details, eligibility criteria, and how to join, please visit: CitizenScienceFoundation.org/study

One Last Step

One of the challenges in this IRB process is that we don’t have a lot of latitude to give regular updates on it as it unfolds. Under most normal circumstances, aspects of the protocol draft and review, legal and liability considerations, and even the stages of approval are kept quiet until formal announcement and start …

Continue reading